Zhejiang Langhua is a comprehensive pharmaceutical company engaged in small molecule Contract Development and Manufacturing Organisation (CDMO) services, as well as the marketing and sourcing of pharmaceutical products. Langhua offers its worldwide partners a One-Stop CDMO solution for small molecule Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms, spanning from pre-clinical stages to commercial supply. With an advanced technology platform and a US-FDA/NMPA/EDQM/WHO approved manufacturing site, supported by a robust environmental, health and safety (EHS) system, Langhua has significantly contributed to the launch of more than 20 new drugs in recent years, ensuring a long-term and sustainable supply of outstanding services and products to its global partners.

Services include:
- Small molecule CDMO services
- Active Pharmaceutical Ingredients (APIs) production
- Finished Dosage Forms
- Marketing and sourcing of pharmaceutical products
- Pre-clinical supply services
- Commercial supply services

Zhejiang Langhua is committed to being the most innovative and reliable CDMO service provider in the world, actively contributing to the availability and affordability of new medicines and ensuring quick access to the public. For more information, please visit wap.langhuapharma.com.